Complement dysregulation in glomerulonephritis.

C3 glomerulonephritis C3 glomerulopathy C3 nephritic factor C3GN C3bBb Complement Dense deposit disease Eculizumab FHR Factor H Factor H-related protein Hemolytic uremic syndrome IgA glomerulonephritis IgA nephropathy Membranoproliferative glomerulonephritis Plasmapheresis Proteinuria Sialic acid Streptococcus aHUS

Journal

Seminars in immunology
ISSN: 1096-3618
Titre abrégé: Semin Immunol
Pays: England
ID NLM: 9009458

Informations de publication

Date de publication:
10 2019
Historique:
pubmed: 13 11 2019
medline: 5 6 2020
entrez: 13 11 2019
Statut: ppublish

Résumé

Glomerulonephritis (GN) refers to a group of renal diseases affecting the glomeruli due to the damage mediated by immunological mechanisms. A large proportion of the disease manifestations are caused by disturbances in the complement system. They can be due to genetic errors, autoimmunity, microbes or abnormal immunoglobulins, like modified IgA or paraproteins. The common denominator in most of the problems is an overactive or misdirected alternative pathway complement activation. An assessment of kidney function, amount of proteinuria and hematuria are crucial elements to evaluate, when glomerulonephritis is suspected. However, the cornerstones of the diagnoses are renal biopsy and careful examination of the complement abnormality. Differential diagnostics between the various forms of GN is not possible based on clinical features, as they may vary greatly. This review describes the known mechanisms of complement dysfunction leading to different forms of primary GN (like IgA glomerulonephritis, dense deposit disease, C3 glomerulonephritis, post-infectious GN, membranous GN) and differences to atypical hemolytic uremic syndrome. It also covers the basic elements of etiology-directed therapy and prognosis of the most common forms of GN. Common principles in the management of GN include treatment of hypertension and reduction of proteinuria, some require immunomodulating treatment. Complement inhibition is an emerging treatment option. A thorough understanding of the basic disease mechanism and a careful follow-up are needed for optimal therapy.

Identifiants

pubmed: 31711769
pii: S1044-5323(19)30084-3
doi: 10.1016/j.smim.2019.101331
pii:
doi:

Substances chimiques

Biomarkers 0
Complement System Proteins 9007-36-7

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

101331

Informations de copyright

Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.

Auteurs

Kati Kaartinen (K)

Department of Nephrology, Abdominal Center, Helsinki University Central Hospital, Helsinki, Finland.

Adrian Safa (A)

Department of Biomedical Sciences, Humanitas University, Milan, Italy; Department of Bacteriology and Immunology, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.

Soumya Kotha (S)

Department of Biomedical Sciences, Humanitas University, Milan, Italy; Department of Bacteriology and Immunology, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.

Giorgio Ratti (G)

Department of Biomedical Sciences, Humanitas University, Milan, Italy; Department of Bacteriology and Immunology, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.

Seppo Meri (S)

Department of Biomedical Sciences, Humanitas University, Milan, Italy; Department of Bacteriology and Immunology, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland; HUSLAB, Helsinki University Central Hospital, Helsinki, Finland. Electronic address: seppo.meri@helsinki.fi.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH